-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Debio-0228 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Debio-0228 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Debio-0228 in Solid Tumor Drug Details: Debio-0228 is under development for...
-
Product Insights
Neurofibroma – Drugs In Development, 2023
Global Markets Direct’s, ‘Neurofibroma - Drugs In Development, 2023’, provides an overview of the Neurofibroma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neurofibroma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Plexiform Neurofibroma – Drugs In Development, 2023
Global Markets Direct’s, ‘Plexiform Neurofibroma - Drugs In Development, 2023’, provides an overview of the Plexiform Neurofibroma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plexiform Neurofibroma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Macular Edema – Drugs In Development, 2023
Global Markets Direct’s, ‘Macular Edema - Drugs In Development, 2023’, provides an overview of the Macular Edema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VIP-236 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. VIP-236 in Colorectal Cancer Drug Details: VIP-236 is under development for the treatment of advanced...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Timolol in Open-Angle Glaucoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Timolol in Open-Angle Glaucoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Timolol in Open-Angle Glaucoma Drug Details:Timolol is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – D-4517 in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - D-4517 in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. D-4517 in Diabetic Macular Edema Drug Details: D-4517 is under development...